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Abstract
Right-sided and left-sided obstructive heart defects (OHDs) are subtypes of congenital heart 
defects, in which the heart valves, arteries, or veins are abnormally narrow or blocked. Previous 
studies have suggested that the development of OHDs involved a complex interplay between 
genetic variants and maternal factors. Using the data from 569 OHD case families and 1644 
control families enrolled in the National Birth Defects Prevention Study (NBDPS) between 1997 
and 2008, we conducted an analysis to investigate the genetic effects of 877 single nucleotide 
polymorphisms (SNPs) in 60 candidate genes for association with the risk of OHDs, and their 
interactions with maternal use of folic acid supplements, and pre-pregnancy obesity. Applying 
log-linear models based on the hybrid design, we identified a SNP in methylenetetrahydrofolate 
reductase (MTHFR) gene (C677T polymorphism) with a main genetic effect on the occurrence of 
OHDs. In addition, multiple SNPs in betaine-homocysteine methyltransferase (BHMT and 
BHMT2) were also identified to be associated with the occurrence of OHDs through significant 
main infant genetic effects and interaction effects with maternal use of folic acid supplements. We 
also identified multiple SNPs in glutamate-cysteine ligase, catalytic subunit (GCLC) and DNA 
(cytosine-5-)-methyltransferase 3 beta (DNMT3B) that were associated with elevated risk of 
OHDs among obese women. Our findings suggested that the risk of OHDs was closely related to a 
combined effect of variations in genes in the folate, homocysteine, or glutathione/transsulfuration 
pathways, maternal use of folic acid supplements and pre-pregnancy obesity.
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INTRODUCTION
Congenital heart defects (CHDs) are abnormalities of the heart or great vessels that are 
present at birth. Each year 1.35 million babies are born worldwide with CHDs [van der 
Linde et al., 2011]. Infant mortality accounted for 48.1% of all mortality resulting from 
CHDs; among those who survived the first year of life, 76.1% of deaths occurred during 
adulthood [Gilboa et al., 2010b]. Most published studies have focused on investigating the 
effects of genetic variants and/or maternal factors on the occurrence of CHDs [Botto et al., 
2004; Kuehl and Loffredo, 2005; Hobbs et al., 2006a; Hobbs et al., 2006b; van Beynum et 
al., 2007; Gilboa et al., 2010a; Weiner et al., 2012]. Both family-based studies [Hobbs et al., 
2006a; van Beynum et al., 2007] and case-control studies [Hobbs et al., 2006b; Weiner et 
al., 2012] revealed a significant association between the methylenetetrahydrofolate reductase 
(MTHFR) gene and the risk of CHDs. It has been suggested that maternal use of folic acid 
supplements within the periconceptional period is associated with a reduced risk of CHDs 
[Botto et al., 2004; Kuehl and Loffredo, 2005], while maternal obesity is associated with an 
elevated risk of CHDs [Watkins and Botto, 2001; Oddy et al., 2009; Gilboa et al., 2010a; 
Mills et al., 2010; Madsen et al., 2013; Brite et al., 2014].
Right-sided and left-sided obstructive heart defects (OHDs), are CHDs that occur when 
heart valves, arteries, or veins are abnormally narrow or blocked [Botto et al., 2007]. Among 
sub-phenotypes of OHDs, pulmonary stenosis, coarctation of the aorta, and aortic stenosis 
account for 8%, 5% and 4% of all CHDs, respectively [van der Linde et al., 2011]. 
Etiologies of the majority of OHDs are unknown. Most OHDs are not associated with 
syndromes and are thought to result from a complex interplay between environmental, 
behavioral, genetic, and epigenetic risk factors [Hobbs et al., 2010]. It has been 
demonstrated that folic acid supplementation within the periconceptional period is 
associated with a reduced risk of OHDs [Botto et al., 2003]. Previous studies have also 
shown that pre-pregnancy obesity is associated with elevated risk of some sub-phenotypes 
of OHDs (e.g. hypoplastic left heart syndrome and pulmonary stenosis) [Gilboa et al., 
2010a; Mills et al., 2010]. It is reported that the lack of periconceptional use of vitamins or 
supplements that contain folic acid may be associated with an excess risk for birth defects 
due to diabetes mellitus [Correa et al., 2012]. We and others have also shown that even if 
obese women receive a standard amount of prenatal folate, they may have an increased 
requirement for folic acid in order to benefit from its protective effect against birth defects 
[Rasmussen et al., 2008; Hobbs et al., 2010; Madsen et al., 2013]. Based on this evidence, it 
is suspected that the observed association between obesity and birth defects may be a greater 
demand for folate in obese individuals. It would then follow that obese women with 
potential dysregulated folate metabolism or transport via genetic variation would be at 
differential risk. We and others have published investigations reporting that women who 
delivered infants with OHDs are more likely to have alterations in metabolites in pathways 
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involving folate, homocysteine, and glutathione [Hobbs et al., 2005a; Hobbs et al., 2005b]. 
These reports have led to the hypothesis that genetic variants in maternal and infant genes 
that encode for enzymes in these metabolic pathways may modify the risk of OHDs.
We conducted this study to evaluate the associations between OHDs and maternal and infant 
genetic variants in pathways related to folate, homocysteine, and glutathione metabolism, 
and to investigate whether the impact of such variants is modified by maternal use of folic 
acid supplements and pre-pregnancy obesity. A comprehensive list of 877 single nucleotide 
polymorphisms (SNPs) from 60 candidate genes involved in metabolic pathways (folate, 
homocysteine, or glutathione/transsulfuration) was studied. We hypothesized that both 
maternal and infant genetic variants involved in folate metabolism were associated with 
OHDs, and some genetic effects also interact with maternal use of folic acid supplements, or 




The study was approved by University of Arkansas for Medical Sciences’ Institutional 
Review Board (IRB) and the National Birth Defects Prevention Study (NBDPS) with 
protocol oversight by the Centers for Disease Control and Prevention (CDC) Center for 
Birth Defects and Developmental Disabilities. All study subjects gave informed consent. For 
minors, informed written consent was obtained from their legal guardian for DNA 
collection.
Study Population
The NBDPS was a family-based case-control study designed to evaluate genetic, 
environmental, and behavior factors associated with the occurrence of major non-syndromic 
birth defects [Yoon et al., 2001]. In this article, we briefly describe the family recruitment 
for the NBDPS. Additional details have been described in a previous publication [Yoon et 
al., 2001]. All families included in this study were enrolled in the NBDPS between 1997 and 
2008. Both cases and controls and their parents were identified through population-based 
birth defects surveillance systems in 10 states (Arkansas, California, Iowa, Massachusetts, 
New Jersey, New York, Texas, Georgia, North Carolina, and Utah). We included 586 case 
families with singleton live-born infants with OHDs and 1702 control families with 
singleton live-born infants without any major structural birth defects. Cases where the 
pregnancy was affected by a known single gene disorder, chromosomal abnormality, or 
syndrome were excluded. Medical records were abstracted by trained health information 
specialists. All cardiac NBDPS case infants were required to have a cardiac defect identified 
by one or more of the following diagnostic tests: echocardiograms, surgical reports, cardiac 
catherizations, and autopsies. All diagnostic tests on case infants were reviewed by a 
pediatric cardiologist to ensure uniform criteria for diagnoses. A classification system 
developed for NBDPS, which incorporated three dimensions of cardiac phenotype, cardiac 
complexity, and extracardiac anomalies, was used to classify cases [Botto et al., 2007]. All 
controls who had DNA samples available, including all family members, mother, father, 
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baby or any combination thereof, were included in our study. The mothers of all 
participating families completed interviews.
Data Collection
Both case and control mothers participated in a one-hour interview carried out by female 
interviewers using a computer-assisted telephone questionnaire [Yoon et al., 2001]. 
Interviews were conducted in English or Spanish [Yoon et al., 2001]. For the present 
analyses, we included interview information about two maternal factors: periconceptional 
folic acid supplement use, and pre-pregnancy obesity. The folic acid supplement use was 
defined as use for at least two months during the exposure window that was defined as one 
month prior to conception and two months after conception. Pre-pregnancy obesity was 
defined as a body mass index (BMI) ≥ 30, while normal weight was defined as a body mass 
index of 18.5 ≤ BMI < 25. Upon completion of the maternal interviews, case and control 
families received a buccal cell collection kit for collecting cheek cell samples from offspring 
and both parents if available [Yoon et al., 2001].
Genotyping and Quality Control
As previously reported by Chowdhury et al [Chowdhury et al., 2012], a custom panel of 
1536 SNPs from 62 genes involved in one of three candidate metabolic pathways (folate, 
homocysteine or glutathione/transsulfuration) or DNA synthesis/repair was selected for 
analysis. Genotyping was performed using 200 ng of whole genome amplified (WGA) DNA 
on the Illumina’s customizable Golden Gate platform [Fan et al., 2006]. Initial genotype 
calls were generated using GenCall, Illumina’s proprietary algorithm. We found that the 
quality of genotype clustering varied substantially from SNP to SNP on the Golden Gate 
custom platform, whether using blood samples or WGA-buccal samples. We therefore 
developed SNPMClust, a bivariate Gaussian model-based genotype calling algorithm, to 
complement the default Illumina GenCall algorithm, and applied very strict quality control 
measures. As described in greater detail by Hobbs et al [Hobbs et al., 2014], we performed a 
pilot study of 94 women who had provided both blood and buccal samples, and among 
genotype calls which passed quality control, we observed a 99.2% concordance rate between 
WGA-buccal DNA and blood-derived DNA. We therefore have confidence in genotypes 
used in our study because of our stringent quality standards.
A total of 4830 individual samples were genotyped, and 279 samples were removed from 
analysis due to study ineligibility, high no-call rates, or high rates of Mendelian 
inconsistency, resulting in an analytical sample consisting of 4551 individuals from 569 case 
and 1644 control families. In the pilot study, we identified 60 SNPs with poor clustering 
behavior even within the blood DNA samples and removed them from consideration. We 
also excluded 10 SNPs with Mendelian error rates > 5%, 389 SNPs with no-call rates > 
10%, 192 SNPs with minor allele frequency (MAF) < 5%, and 8 SNPs that deviated 
significantly from Hardy-Weinberg Equilibrium (HWE) in at least one racial group (p < 
10−4). The HWE analyses were performed within each racial group using the genotype data 
from parents of controls. The final analysis dataset included genotype data from 4551 (94%) 
individuals on 877 (57%) SNPs.
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Descriptive statistics were expressed as mean (standard deviation) for continuous variables, 
and frequency (percentage) for categorical variables. Because both case-parental and 
control-parental triads were genotyped, a hybrid design was used for statistical analysis 
[Weinberg and Umbach, 2005]. The use of a hybrid design allows (1) the evaluation of 
maternal and infant genetic effects simultaneously, while adjusting for the effect of each 
other (i.e. both maternal and infant genotypes are included in one model fitting); (2) 
protection of infant genetic effects from bias due to population admixture, and (3) 
exploration of interactions between genetic variants and non-genetic factors.
Two different sets of log-linear models were fitted. The first set was used to estimate genetic 
(G) effects only, whereas the second set was used to estimate gene × non-genetic (G × E) 
interaction effect.
G Model: a main effects model was fitted for each SNP as a function of mating type, case/
control status (D), an interaction between case/control status and maternal genotype (D × 
M), and an interaction between case/control status and infant genotype (D × C). This model 
was designated to assess the main effects of maternal and infant genotypes on the risk of 
OHDs.
G × E Model: an interaction model was fitted for each SNP as a function of mating type, an 
interaction between mating types and a non-genetic factor (E), case/control status (D), an 
interaction for maternal genotype (D × M), an interaction for infant genotype (D × C), a 
three-way interaction for maternal genotype (D × E × M), and a three-way interaction for 
infant genotype (D × E × C). This model was designed to evaluate whether there were 
significant interactions between maternal and/or infant genotype and non-genetic factor.
When fitting the models, mating symmetry was assumed, and thus six different mating types 
were used. We also assumed multiplicative risk per allele (additive genetic effect), under 
which, the indicators for both maternal and infant genotypes were defined as continuous 
variables representing the number of copies of the variant allele (0, 1 or 2). This also implied 
that the relative risk (RR) of having two copies of variant allele was the square of the RR of 
having one copy of variant allele comparing to zero copies of variant allele. G × E Model 
was fitted for each E factor respectively.
We referred to the Bayesian false-discovery probabilities (BFDPs) for evaluating the chance 
of false-positive associations using the relative risk estimates and their 95% confidence 
intervals (CIs) obtained from the log-linear models [Wakefield, 2007]. BFDP is employed to 
find a balance between the relative costs of false negative and false positive; in the results 
section, we reported associations where BFDP < 0.80, which is a commonly used threshold 
suggested by Wakefield [Wakefield, 2007; Liu et al., 2010; Oh et al., 2010; Park et al., 
2010]. Consistent with a candidate gene study of multifactorial disease, in which the risk 
contribution of any single SNP is expected to be moderate, we specified the prior 
distribution on the odds ratio for associated SNPs such that the 97.5th centile was equal to 
1.5, and set the prior probability of association at any given SNP at 5%. Patterns of linkage 
disequilibrium (LD) between significant SNPs from the same gene were constructed. Data 
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were analyzed using the LEM [Vermunt, 1997] software for fitting log-linear models, R 
v3.0.2 [Team, 2013] for computing descriptive statistics and BFDPs, and HaploView 4.2 
[Barrett, 2009] for developing LD maps.
RESULTS
Population Characteristics
The final sample included 569 case families and 1,644 control-families. The distribution of 
the sub-phenotypes of OHDs among 569 cases is displayed in Figure 1. Table I summarizes 
the maternal demographics and behaviors for case and control-families respectively. Case 
mothers were marginally older (28.3 years vs. 27.5 years, respectively), and more likely to 
be overweight or obese than control mothers. The race-ethnicity distribution showed small 
differences with more Caucasian (non-Hispanic) and African-American case mothers than 
control mothers (73% vs. 69%, and 11% vs. 9%, respectively).
Genetic variants only
A total of 877 SNPs within 60 genes were included in the final analysis. Maternal genotypes 
for six SNPs from four genes [Cystathionine Gamma-Lyase (CTH); 
methylenetetrahydrofolate reductase (MTHFR); O-6-methylguanine-DNA methyltransferase 
(MGMT), and methylenetetrahydrofolate dehydrogenase (MTHFD1)] were identified to be 
significantly associated with the occurrence of OHDs based on G Model (Table II). 
Similarly, infant genotypes for 24 SNPs from 13 genes [MTHFR; transcobalamin II (TCN2); 
betaine--homocysteine S-methyltransferase 2 (BHMT2); glutaredoxin (thioltransferase) 
(GLRX); betaine--homocysteine S-methyltransferase (BHMT); CTH; superoxide dismutase 2 
(SOD2); glutamate-cysteine ligase, catalytic subunit (GCLC); nitric oxide synthase 3 
(NOS3); folate receptor 1 (FOLR1); MGMT; RFC1; and 5-methyltetrahydrofolate-
homocysteine methyltransferase reductase (MTRR)] were identified to be significantly 
associated with the occurrence of OHDs (Table II). The maternal genotype for the SNP 
rs1801133 within the MTHFR gene was identified to be significant (BFDP=0.63). The risk 
of delivering infants with OHDs among women carrying one T allele for rs1801133 was 
estimated to be 1.28 (95% CI: 1.08–1.51) times more than that among women carrying no 
copy of the T allele. Accordingly, the risk among women carrying two T alleles for 
rs1801133 was 1.64 (95% CI: 1.17–2.28) times the risk among those carrying no copy of the 
T allele. As mentioned above, the estimated RR (95% CI) for carrying two copies of the risk 
allele was the square of the estimated RR (95% CI) for carrying one copy of the risk allele 
with 0 copies of the risk allele as the reference group. For simplicity, only the estimated RR 
(95% CI) for carrying one copy of the risk allele compared to 0 copies was reported in the 
following results.
The infant genotype for the same SNP was found to be significantly associated with the risk 
of OHDs with opposing effects. The risk of OHDs among infants carrying one T allele was 
estimated to be 31% (95% CI: 16%–44%) less than those carrying no copy of the T allele. 
Besides, infant genotypes for 3 SNPs (rs9621049, rs4820886, rs4820887) within TCN2 gene 
and 5 SNPs (rs1422086, rs557302, rs625879, rs526264, rs542721) within BHMT2 gene 
were found to have BFDP < 0.8. Among them, rs9621049 within TCN2 and rs1422086 
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within BHMT2 were the SNPs with the smallest BFDP within their respective gene. The 
infant AG genotype for rs9621049 increased the risk of OHDs by 53% (95% CI: 1.21–1.93) 
compared to the GG genotype (BFDP=0.27). Similarly, the risk of OHDs increased by 32% 
(95% CI 1.11–1.58) for infants’ carrying AC genotype for rs1422086 compared to those 
carrying AA genotype (BFDP=0.44).
Genetic variants and folic acid supplementation
Maternal use of folic acid supplements may modify the impact of either maternal or infant 
genetic variants, or both. The interactive effects between maternal use of folic acid 
supplements and genetic variants may not be evident when evaluating the main effects of 
genetic variants only. Although maternal uses of folic acid supplements were similar in case 
(58%) and control (55%) mothers, the proportion of folic acid supplement use was 
significantly different among different race/ethnicity groups (p < 0.001), with 65% (n=1004) 
non-Hispanic Caucasian users compared to 33% (n=68) African-American users and 33% 
(n=116) Hispanic users. Given the lower numbers of African-American and Hispanic 
women, G × E Model was fit to evaluate interaction between each SNP and folic acid 
supplement use among Caucasians only.
Maternal genotypes for 11 SNPs in betaine-homocysteine methyltransferase (BHMT and 
BHMT2) and infant genotypes for two SNPs in BHMT gene significantly associated with 
OHDs through interactions with folic acid supplement use (Table III). For example, folic 
acid supplement users who carried the AG genotype for rs557302 had an increased risk of 
delivering infants with OHDs compared to those carrying the GG genotype (RR: 1.40; 95% 
CI: 1.12–1.74). In contrast, no significant difference was found among women who did not 
use folic acid supplements (RR: 0.74, 95% CI: 0.55–1.01). Relative risks of OHDs for 
infants carrying AG genotype for rs557302 (compared to AA) showed that among mothers 
who used folic acid supplements, the risk of OHDs was reduced by 32% (95% CI: 14%–
46%). Seven out of nine significant SNPs in the BHMT2 gene were determined to be in high 
LD (D′ ≥0.96) (Fig 2). Multiple SNPs (e.g. rs557302) were also found to be significantly 
associated with OHD risk based on the G Models.
Genetic variants and obesity
Maternal obesity has been found to play an important role in cardiogensis and the 
occurrence of CHDs in many published studies [Oddy et al., 2009; Gilboa et al., 2010a; 
Madsen et al., 2013]. In our analyses, a main effect of the association between OHDs and 
pre-pregnancy obesity compared to normal weight resulted in a RR=1.37 (95% CI: 1.15–
1.63; p=0.001). To evaluate how maternal obesity modified the association between OHDs 
and genetic variants, G × E Model was fit to evaluate the interaction between each SNP and 
pre-pregnancy obesity.
We identified maternal genotypes for 19 SNPs and infant genotypes for 32 SNPs that 
interacted with pre-pregnancy obesity to increase the risk of OHDs (Table IV and Fig 3). 
Among these 51 SNP × obesity interactions, there were 10 interactions for which genetic 
variants appeared to be protective against OHD in normal weight women yet putative among 
obese women. In the remaining 41 interactions, the risk of OHD was increased among obese 
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women who did not carry the wild type genotype. Among 19 significant maternal SNPs, 
rs761142 in the GCLC gene had the smallest interactive BFDP=0.56, 3 other SNPs on the 
same gene (rs572494, rs1555906, rs13212365) had a BFDP <0.80. Obese women carrying 
the AC genotype for rs761142 had a 57% (95% CI: 1.14–2.15) increased risk of having 
infants with OHDs compared to those carrying the AA genotype. The remaining significant 
maternal SNPs were present in the following genes: glycine N-methyltransferase (GNMT); 
DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B); glutathione synthetase (GSS); 
microsomal glutathione S-transferase 1 (MGST1); MGMT;, methionine adenosyltransferase 
I, alpha (MAT1A); serine hydroxymethyltransferase 1 (SHMT1), and; glutathione peroxidase 
2 (GPX2).
Infant SNPs found to be significantly associated with OHDs through interactions with pre-
pregnancy obesity are displayed in the bottom panel Table IV and Figure 4. We identified 
11 SNPs in the DNMT3B gene; four SNPs in the GCLC gene; three SNPs in the GLRX gene; 
three SNPs in the tRNA aspartic acid methyltransferase 1 (TRDMT1) gene; two SNPs in the 
GSS gene, and; one SNP in the remaining genes including MGMT, glutathione reductase 
(GSR), glutathione S-transferase pi 1 (GSTP1), microsomal glutathione S-transferase 1 
(MGST1), BHMT, superoxide dismutase 3 extracellular (SOD3), DNA-methyltransferase 3 
alpha (DNMT3A), methionine adenosyltransferase II, alpha (MAT2A), NOS3; and 
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate synthetase (MTHFD1) genes respectively. The most 
significant infant SNP × obesity interaction was that with the SNP rs6058893 among obese 
women; this SNP was within the DNMT3B gene and its BFDP equaled to 0.15. Among 
obese women, infant AG genotype for rs6058893 was associated with elevated relative risk 
of OHDs by 1.73 (95% CI: 1.28–2.34) compared to the GG genotype. In contrast, among 
normal-weight women, infants with AG genotype for rs6058893 had a reduced risk of 
OHDs with a RR=0.75 (95% CI: 0.58–0.97) compared to infants of normal weight women 
who carried the GG genotype. There was no significant main effect of any of the SNPs 
discussed above. Eleven out of 13 significant maternal or infant SNPs in the DNMT3B gene 
were determined to be in high LD (D′ ≥0.9) (Figure 5). Similar models were fitted among 
Caucasians only, and due to relatively smaller sample size and less power, a subset of the 
above SNPs was identified (data not shown). A main effect of the association between 
OHDs and pre-pregnancy overweight compared to normal weight resulted in a RR=1.27 
(95% CI: 1.07–1.51; p=0.007). An additional G × E Model was fit to evaluate the interaction 
between each SNP and pre-pregnancy overweight, and the results are shown in 
Supplemental Table S1 (in supporting information online).
DISCUSSION
Our findings indicate that multiple genetic variants in genes involved in the folate, 
homocysteine or glutathione/transsulfuration pathways have modest effects on the risk of 
OHDs through either genetic main effects or interactions with maternal use of folic acid 
supplements, and pre-pregnancy obesity. These findings provide insights into the genetic 
susceptibility of OHDs. Among 877 SNPs involved in the folate, homocysteine, glutathione/
transsulfuration pathways, multiple SNPs were identified to influence risk of OHDs. All six 
SNPs with significant maternal effects were located within four genes (CTH, MTHFR, 
Tang et al. Page 8













MGMT, and MTHFD1). Among 24 SNPs with significant infant effects, minor alleles of 16 
SNPs within eight genes (TCN2, BHMT2, BHMT, SOD2, GCLC, FOLR1, and MTRR) were 
associated with increased OHD risks, while minor alleles of eight remaining SNPs within 
seven genes (MTHFR, BHMT2, GLRX, GLRX, BHMT, NOS3, MGMT, and RFC1) were 
associated with decreased OHD risks.
Further, multiple SNPs were significantly associated with risks of OHDs through their 
interactions with maternal obesity and folic acid supplement use. Among women who used 
folic acid supplements during the periconceptional period, the maternal genotype of eight 
SNPs within two genes (BHMT2 and BHMT), and the infant genotype of one SNP within 
BHMT2 genes were associated with decreased risks of OHDs. In contrast, among women 
who did not use supplements, five maternal SNPs within the same two genes increased the 
risk of OHDs.
Among women who were obese before pregnancy, maternal genotypes of 18 SNPs in nine 
genes (GCLC, GNMT, GCLM, DNMT3B, MGST1, MGMT, MAT1A, SHMT1, and GPX2) 
were associated with an increased risk of OHDs, while among women who had normal 
weight before pregnancy, maternal genotypes of only three SNPs present in three genes 
(GCLC, GSS, and GPX2) deceased the occurrence of OHDs. Similarly, infant genotypes of 
28 SNPs within 14 genes (DNMT3B, GCLC, GLRX, MGMT, GSR, GSTP1, BHMT, SOD3, 
TRDMT1, GSS, DNMT3A, MAT2A, NOS3, and MTHFD1) increased the occurrence of 
OHDs, while infant genotypes of 11 SNPs within three genes (DNMT3B, GLRX, and 
MGST1) decreased the occurrence of OHDs.
The rs1801133 SNP (i.e. C677T polymorphism) within MTHFR gene was identified to be 
significantly associated with the occurrence of OHDs, which was in concordance with 
several previous findings [Junker et al.; Wenstrom et al.; Lee et al., 2005; van Beynum et al., 
2006; Weiner et al., 2012; Yin et al., 2012]. However, evidence of association between 
C677T polymorphism and CHDs has been less consistent for some other studies. A recent 
meta-analysis of 7697 CHD cases and 13125 controls suggested the presence of association 
between the C677T polymorphism and CHDs with an estimated odds ratio of 1.25 (95% CI: 
1.03–1.51) but with substantial heterogeneity among contributing studies and evidence of 
publication bias [Mamasoula et al., 2013]. The MTHFR enzyme catalyzes the irreversible 
conversion of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the methyl 
donor for homocysteine remethylation to methionine [Weiner et al., 2012]. The T allele of 
the MTHFR C677T polymorphism is associated with reduced activity of MTHFR, DNA 
hypomethylation [van der Put et al., 1998; Castro et al., 2004] and increased plasma 
homocysteine level [Kumar et al., 2005; DeVos et al., 2008]. Our data indicates that the 
maternal genotype for rs1801133 is associated with an increased risk of OHDs at an 
estimated RR=1.28 (95% CI: 1.08–1.51), however, the infant genotype for the same SNP is 
associated with a reduced risk of OHDs at an esitmated RR=0.69 (95% CI: 0.56–0.84). The 
reason for this seemingly conflicting data has not been investigated, but may be related to 
different roles for folate and one-carbon metabolism metabolic programs between the 
mother and the developing embryo. The two major functions of folate and one-carbon 
metabolism are DNA synthesis and DNA methylation. The DNA methylation pathway is 
also responsible for glutathione production. The mother’s metabolism has to support the 
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developing embryo with nutrients as well as protecting the embryo from harm by 
environmental factors and oxidative stress. In this case, the mother’s use of folate and one-
carbon metabolism may be skewed toward the production of the amino acids methionine and 
cysteine for glutathione synthesis, which is necessary for protection of mother and embryo 
from harmful reactive oxygen species. The developing embryo, on the other hand, needs 
large quantities of deoxynucleotide triphosphate precursor pools that are required for error-
free DNA synthesis. There are other published studies reporting SNPs having opposing 
effects [Shi et al., 2007; Adkins et al., 2008]. For example, Adkins et al [Adkins et al., 2008] 
found that maternal haplotypes in the insulin and IGF2 had a significant association with 
small for gestational age (SGA) birth, in newborns however, the opposite haplotype 
conferred risk of SGA. The authors conclude that these haplotypes have an opposing 
influence on the growth rate of the embryo. Shi et al [Shi et al., 2007] in a reanalysis of 
existing orofacial cleft data, investigated both fetal and maternal effects of the IRF6 gene. 
They found a maternal haplotype consisting of 13 SNPs that conferred increased risk. 
However, in offspring analysis, the risk conferring allele for each of these SNPs was the 
opposite allele from the maternal risk allele. After further analysis, imprinting was 
discounted as a possible explanation for these opposing effects. They postulate that the 
unlikely result that the same haplotype could be protective against clefts in the embryo when 
carried by the mother, but could be deleterious when carried by the embryo could be a result 
of the same genes having very different functions in the mother and the developing embryo.
Our study revealed associations between OHDs and SNPs with the BHMT, BHMT2 genes 
through both infant genetic main effects, and maternal and infant SNP× folic acid 
supplement use interactions. BHMT catalyzes the remethylation of homocysteine. BHMT2 
encodes a protein that is 73% identical to BHMT [Li et al., 2008]. For both BHMT and 
BHMT2 genes, their impact on common diseases remains unknown.
The GCLC gene was identified to be significantly associated with elevated risk of OHDs 
among obese mothers. The GCLC gene is the rate limiting step in glutathione synthesis and 
is dependent on cellular availability of cysteine. Cellular glutathione protects developing 
embryos from harmful xenobiotic and environmental exposures [Hansen et al., 2004] 
creating an optimal environment for the developing embryo, and oxidative stress has been 
implicated in teratogenesis [Wells et al., 2009]. Nevertheless, the haplotype tagging SNPs 
have not been identified on the GCLC gene for common diseases.
Our analysis also revealed a strong association between polymorphisms in DNMT3B gene 
and increased risk of OHDs among obese mothers. The DNMT3B gene encodes a DNA 
methyltransferase which is thought to function in de novo methylation, rather than 
maintenance methylation [Shirohzu et al., 2002]. The protein localizes primarily to the 
nucleus and its expression is developmentally regulated [Shirohzu et al., 2002]. A positive 
association has been noted between mutations in the DNMT3B gene and immunodeficiency, 
centromere instability and facial anomalies (ICF) syndrome [Hansen et al., 1999; Shirohzu 
et al., 2002]. Our study provided preliminary evidence that polymorphisms in DNMT3B 
may be associated with an increased risk of OHDs in combination with pre-pregnancy 
obesity.
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There are several strengths of this study including its large size, population-based 
ascertainment of cases, and a rigorous analytic inquiry into potential gene-environment 
interactions on OHD risk. There are also limitations. First, buccal cell collection kits in 
collecting DNA samples created a disparity among the quality of the DNA samples. Due to 
poor clustering in GenomeStudio and application of conservative standards in subsequent 
quality checks, the number of SNPs remained in the analysis reduced from 1534 to 877. 
Secondly, based on the hybrid design, the log-linear model can be extended to include more 
than one non-genetic factor; for example, the effects of periconceptional folic acid 
supplement use and pre-pregnancy obesity on the risk of OHDs can be evaluated 
simultaneously. However, the sample size required to test for more than 1st order 
interactions among non-genetic factors is substantially larger, thus we were relegated to 
assess the non-genetic factors independently from each other. In addition, the potential 
confounding effects from other environmental/behavior factors were not considered. 
Thirdly, none of the identified SNPs would remain statistically significant after Bonferroni 
correction, which is widely considered overly conservative. We report both unadjusted p-
values and BFDPs. The BFDP is a Bayesian measure of the probability of false discovery, 
and has been widely used in candidate gene-based studies when there is a priori knowledge 
that the genes are likely to be associated with the disease. Last, due to the relatively smaller 
sample size for each sub-phenotype, the analysis was not replicated among each sub-
phenotype of OHDs. Analyses targeted to specific sub-phenotypes may have revealed 
stronger associations that were muted by the overall grouped analyses.
Our results provide some evidence for gene × environment interaction in the etiologies of 
OHDs. However, findings are preliminary and will need to be replicated in another 
population. Further studies, will need to incorporate functional genetics and targeted deep 
sequencing while improving and enhancing information collected on environmental and 
maternal factors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Sub-phenotype information. Distribution of sub-phenotypes of right-sided and left-sided 
obstructive heart defects among 569 cases
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LD map for significant SNPs on BHMT2 gene. The patterns of LD between SNPs on 
BHMT2 gene that were identified to have significant maternal and/or infant SNP × folic 
acid supplementation interactions.
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Interactions between maternal genes and maternal obesity. Estimated relative risks and 95% 
confidence intervals for maternal SNPs with significant SNP × obesity interactions on the 
risk of right-sided and left-sided obstructive heart defects. (A) Maternal genetic effects 
among normal-weight women; and (B) Maternal genetic effects among obese women.
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Interactions between infant genes and maternal obesity. Estimated relative risks and 95% 
confidence intervals for infant SNPs with significant SNP × obesity interactions on the risk 
of right-sided and left-sided obstructive heart defects. (A) Infant genetic effects among 
normal-weight women; and (B) Infant genetic effects among obese women.
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LD map for significant SNPs on DNMT3B gene. The patterns of LD between SNPs on 
DNMT3B gene that were identified to have significant maternal and/or infant SNP × obesity 
interactions.
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Table 1
Maternal Characteristics
Case (N=569) Control (N=1,644
Age at delivery 28.3 (6.0) 27.5 (6.0)
Mother’s race
 African American 61 (11%) 144 (9%)
 Caucasian 418 (73%) 1,135 (69%)
 Hispanic 66 (12%) 286 (17%)
 Others 24 (4%) 79 (5%)
Mother’s education
 <12 years 73 (13%) 217 (13%)
 High school degree or equivalent 140 (25%) 412 (25%)
 1–3 years of college 174 (31%) 454 (28%)
 At least 4 years of college or Bachelor degree 182 (32%) 559 (34%)
 Missing information 0 2
Household income
 < $10,000 70 (13%) 236 (15%)
 $10,000 to < $30,000 163 (30%) 408 (27%)
 $30,000 to < $50,000 131 (24%) 348 (23%)
 ≥ $50,000 183 (33%) 539 (35%)
 Missing information 22 113
Folic acid supplement use1
 Yes 332 (58%) 912 (55%)
 No 237 (42%) 732 (45%)
Alcohol consumption2
 No 450 (80%) 1,250 (76%)
 Yes 115 (20%) 390 (24%)
 Missing information 4 4
Cigarette smoking3
 No 491 (86%) 1,356 (83%)
 Yes 78 (14%) 287 (17%)
 Missing information 0 1
Pre-pregnancy BMI
 Underweight (BMI < 18.5) 14 (3%) 74 (5%)
 Normal weight (18.5 ≤ BMI < 25) 261 (47%) 878 (55%)
 Overweight (25 ≤ BMI < 30) 148 (27%) 361 (23%)
 Obese (≥ 30) 130 (24%) 281 (18%)
 Missing information 16 50
Summary statistics were expressed as mean (standard deviation) for age, and frequency (percentage) for other categorical variables.
1
Folic acid supplement use was defined as use for at least two months during the exposure window that was defined as one month prior to 
conception and two months after conception.
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2
Alcohol consumption is defined maternal alcohol consumption during the first trimester.
3
Cigarette smoking is defined as maternal tobacco use during the first trimester.
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